Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
Rhea-AI Summary
Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for treating glaucoma and retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join the call by dialing +1-888-596-4144 with conference ID: 698002.
A live and recorded webcast of the event will be accessible through the "Event Calendar" page in the "Investors" section of Iridex's website at www.iridex.com.
Positive
- Company maintains Nasdaq listing status (IRIX)
- Demonstrates market leadership in laser-based medical systems for glaucoma and retinal diseases
Negative
- None.
News Market Reaction
On the day this news was published, IRIX declined 0.84%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex (IRIX) release Q1 2025 earnings?
How can investors join Iridex's Q1 2025 earnings call?
What time is Iridex's Q1 2025 earnings conference call?
What medical products does Iridex (IRIX) specialize in?
Where can I find Iridex's Q1 2025 earnings webcast?
